Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy

被引:0
作者
M Kamrava
A H Kesarwala
R A Madan
E Lita
A Kaushal
K-Y Tsang
D J Poole
S M Steinberg
T Ferrara
W Dahut
J Schlom
J L Gulley
机构
[1] University of California at Los Angeles,Department of Radiation Oncology
[2] Radiation Oncology Branch,undefined
[3] Center for Cancer Research,undefined
[4] National Cancer Institute,undefined
[5] National Institutes of Health,undefined
[6] Laboratory of Tumor Immunology and Biology,undefined
[7] Center for Cancer Research,undefined
[8] National Cancer Institute,undefined
[9] National Institutes of Health,undefined
[10] Medical Oncology Branch,undefined
[11] Center for Cancer Research,undefined
[12] National Cancer Institute,undefined
[13] National Institutes of Health,undefined
[14] Biostatistics and Data Management Section,undefined
[15] Center for Cancer Research,undefined
[16] National Cancer Institute,undefined
[17] National Institutes of Health,undefined
来源
Prostate Cancer and Prostatic Diseases | 2012年 / 15卷
关键词
radiotherapy; therapeutic vaccine; immunotherapy; PROSTVAC;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:289 / 295
页数:6
相关论文
共 121 条
[1]  
Hanks GE(2003)Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92–02 J Clin Oncol 21 3972-3978
[2]  
Pajak TF(2007)Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 475-487
[3]  
Porter A(2005)Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 1233-1239
[4]  
Grignon D(2007)Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option Cancer 110 1405-1416
[5]  
Brereton H(2004)Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer 100 1283-1292
[6]  
Venkatesan V(2003)Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era Int J Radiat Oncol Biol Phys 57 915-928
[7]  
Dearnaley DP(2007)Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature Cancer 110 1417-1428
[8]  
Sydes MR(2005)Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer Clin Cancer Res 11 3353-3362
[9]  
Graham JD(2008)Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant Clin Cancer Res 14 5284-5291
[10]  
Aird EG(2006)A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Clin Cancer Res 12 1260-1269